Organisation paid for research Program year 2025 Source: CMS Open Payments

Southcoast Hospitals Group Inc

Neither a doctor nor a teaching hospital

Research payments

$932,801

151 payments

Through program year 2025, Southcoast Hospitals Group Inc is reported as receiving $932,801 in research payments, across 151 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$299,525	40
2024	Research	$262,567	19
2023	Research	$121,913	28
2022	Research	$64,998	21
2021	Research	$91,630	21
2020	Research	$86,320	18
2019	Research	$5,848	4

Breakdown

Who paid Research payments · program years 2019–2025

Boston Scientific Corporation $299,758 84 payments
Pfizer Inc. $222,104 21 payments
AstraZeneca Pharmaceuticals LP $187,044 3 payments
Eli Lilly and Company $120,352 14 payments
Genentech, Inc. $103,542 29 payments

Studies the money was for Research payments · program years 2019–2025

A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole $187,044 3 payments
A Randomized Phase 3 Openlabel Study to Evaluate Sgnb6a Compared With Docetaxel in Adult Subjects With Previously Treated Nonsmall Cell Lung Cancer $182,151 12 payments
Tiragolumab Tecentriq VS Durvalumab in Unresectable Stage III Nsclc $82,776 18 payments
Avant Guard $72,259 7 payments
Reprise IV $62,371 5 payments
Ember-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant VS Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for Er+, Her2- Early Breast Cancer With An Increased Risk of Recurrence $58,918 5 payments
A Study of Enfortumab Vedotin Asg22ce As Monotherapy Or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer $39,953 9 payments
Frozen Af $39,944 9 payments
Simplaafy $31,507 9 payments
Emonarcher: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, Her2+ Early Breast Cancer Who Have Completed Adjuvant Her2-Targeted Therapy $25,772 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.